glp 1 cardiac protection Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Bridging the gap between GLP1-receptor

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month

Supports a gut environment where GLP-1 thrives*: Eriomin and Feiolix promote a healthy metabolic environment by supporting gut health and maintaining balanced oxidative stress and inflammation responses.

Learn how weight loss drugs affect oral health, causing side effects like dry mouth, and discover 6 tips to prevent damage.

Tirz epatide has undergone extensivePhase 3 clinical evaluation in large, controlled trials

Are you on a journey to shed those extra pounds and achieve a healthier you